Positive Tagrisso Data Boost AstraZeneca's Lung Cancer Ambitions

Latest data from AstraZeneca's Tagrisso will help the company to convert the lung cancer drug's conditional approvals to full approvals, and boost reimbursement negotiations.

Lung

More from R&D

More from Scrip